SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 25, 2015
Bone Biologics Corporation
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
175 May Street, Suite 400, Edison, NJ
|(Address of principal executive offices)||(Zip Code)|
Registrantís telephone number, including area code: (732) 661-2224
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) Election of Director.
Effective September 25, 2015, the Board of Directors of Bone Biologics Corporation appointed Dr. Ben Wu to the Board of Directors to serve as a director with a term to expire until such time as his successor is duly elected. Dr. Ben Wu, M.D. is a founder and has served as a member of the Companyís Scientific Advisory Board since 2005.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Bone Biologics Corporation|
|Dated: October 1, 2015|
|By:||/s/ Steve LaNeve|
|Chief Executive Officer|